IL298608A - שיטות לטיפול בהפרעות הקשורות להזדקנות - Google Patents

שיטות לטיפול בהפרעות הקשורות להזדקנות

Info

Publication number
IL298608A
IL298608A IL298608A IL29860822A IL298608A IL 298608 A IL298608 A IL 298608A IL 298608 A IL298608 A IL 298608A IL 29860822 A IL29860822 A IL 29860822A IL 298608 A IL298608 A IL 298608A
Authority
IL
Israel
Prior art keywords
methods
cells
related disorders
treating aging
tgf
Prior art date
Application number
IL298608A
Other languages
English (en)
Original Assignee
Hcw Biologics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2020/035598 external-priority patent/WO2021247003A1/en
Application filed by Hcw Biologics Inc filed Critical Hcw Biologics Inc
Publication of IL298608A publication Critical patent/IL298608A/he

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Electroluminescent Light Sources (AREA)
  • Treatments Of Macromolecular Shaped Articles (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
IL298608A 2020-06-01 2021-06-01 שיטות לטיפול בהפרעות הקשורות להזדקנות IL298608A (he)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063032933P 2020-06-01 2020-06-01
PCT/US2020/035598 WO2021247003A1 (en) 2020-06-01 2020-06-01 Methods of treating aging-related disorders
US202063118536P 2020-11-25 2020-11-25
PCT/US2021/035285 WO2021247604A1 (en) 2020-06-01 2021-06-01 Methods of treating aging-related disorders

Publications (1)

Publication Number Publication Date
IL298608A true IL298608A (he) 2023-01-01

Family

ID=76523519

Family Applications (1)

Application Number Title Priority Date Filing Date
IL298608A IL298608A (he) 2020-06-01 2021-06-01 שיטות לטיפול בהפרעות הקשורות להזדקנות

Country Status (7)

Country Link
EP (1) EP4157460A1 (he)
JP (1) JP2023527869A (he)
KR (1) KR20230031280A (he)
AU (1) AU2021283199A1 (he)
CA (1) CA3184756A1 (he)
IL (1) IL298608A (he)
WO (1) WO2021247604A1 (he)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230125173A1 (en) * 2021-08-11 2023-04-27 HCW Biologics, Inc. Multi-chain chimeric polypeptides and use thereof in the treatment of liver diseases
WO2023168363A1 (en) * 2022-03-02 2023-09-07 HCW Biologics, Inc. Method of treating pancreatic cancer
CN116199787A (zh) * 2022-08-02 2023-06-02 四川大学华西医院 一种基于uPA的GFD结构域构建的嵌合抗原受体免疫细胞制备及其应用

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9324807D0 (en) 1993-12-03 1994-01-19 Cancer Res Campaign Tech Tumour antibody
US6117980A (en) 1997-02-21 2000-09-12 Genentech, Inc. Humanized anti-IL-8 monoclonal antibodies
JP2001206899A (ja) 1999-11-18 2001-07-31 Japan Tobacco Inc ＴＧＦ−βＩＩ型受容体に対するヒトモノクローナル抗体及びその医薬用途
DK1345969T3 (da) 2000-12-26 2010-11-29 Inst Nat Sante Rech Med Anti-CD28-antistof
WO2003104425A2 (en) 2002-06-07 2003-12-18 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Novel stable anti-cd22 antibodies
KR20050058486A (ko) 2002-08-30 2005-06-16 자이단호진 가가쿠오요비겟세이료호겐쿠쇼 인간형 항인간 인터루킨-6 항체 및 항체 단편
EP1400534B1 (en) 2002-09-10 2015-10-28 Affimed GmbH Human CD3-specific antibody with immunosuppressive properties
ATE514713T1 (de) 2002-12-23 2011-07-15 Wyeth Llc Antikörper gegen pd-1 und ihre verwendung
RU2005132458A (ru) 2003-03-21 2006-03-20 Уайт (Us) Лечение иммунологических расстройств с использованием агонистов интерлейкина-21/рецептора интерлейкина-21
US9005613B2 (en) 2003-06-16 2015-04-14 Immunomedics, Inc. Anti-mucin antibodies for early detection and treatment of pancreatic cancer
NZ549040A (en) 2004-02-17 2009-07-31 Schering Corp Use for interleukin-33 (IL33) and the IL-33 receptor complex
EP1730194B1 (en) 2004-03-30 2011-11-02 Yissum Research Development Company of the Hebrew University of Jerusalem Bi-specific antibodies for targeting cells involved in allergic-type reactions, compositions and uses thereof
EP1877444A2 (en) 2005-04-26 2008-01-16 Pfizer, Inc. P-cadherin antibodies
GB0510790D0 (en) 2005-05-26 2005-06-29 Syngenta Crop Protection Ag Anti-CD16 binding molecules
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US8092804B2 (en) 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
DK2274008T3 (da) 2008-03-27 2014-05-12 Zymogenetics Inc Sammensætninger og fremgangsmåder til hæmning af PDGFRBETA og VEGF-A
DK3216803T3 (da) 2008-06-25 2020-06-02 Novartis Ag Stabile og opløselige antistoffer, der hæmmer vegf
WO2010006060A2 (en) 2008-07-08 2010-01-14 Abbott Laboratories Prostaglandin e2 dual variable domain immunoglobulins and uses thereof
WO2010017103A2 (en) 2008-08-04 2010-02-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic Fully human anti-human nkg2d monoclonal antibodies
US8298533B2 (en) 2008-11-07 2012-10-30 Medimmune Limited Antibodies to IL-1R1
CN108997498A (zh) 2008-12-09 2018-12-14 霍夫曼-拉罗奇有限公司 抗-pd-l1抗体及它们用于增强t细胞功能的用途
NZ598929A (en) 2009-09-01 2014-05-30 Abbvie Inc Dual variable domain immunoglobulins and uses thereof
DE102009045006A1 (de) 2009-09-25 2011-04-14 Technische Universität Dresden Anti-CD33 Antikörper und ihre Anwendung zum Immunotargeting bei der Behandlung von CD33-assoziierten Erkrankungen
TW201119676A (en) 2009-10-15 2011-06-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
US9085623B2 (en) 2010-02-11 2015-07-21 Alexion Pharmaceuticals, Inc. Therapeutic methods using anti-CD200 antibodies
EP2560994B1 (en) 2010-04-08 2016-10-12 JN Biosciences LLC Antibodies to cd122
ES2682078T3 (es) 2010-06-11 2018-09-18 Kyowa Hakko Kirin Co., Ltd. Anticuerpo anti-TIM-3
JP2013537415A (ja) 2010-08-03 2013-10-03 アッヴィ・インコーポレイテッド 二重可変ドメイン免疫グロブリンおよびその使用
JP2012034668A (ja) 2010-08-12 2012-02-23 Tohoku Univ ヒト型化抗ｅｇｆｒ抗体リジン置換可変領域断片及びその利用
GB201103955D0 (en) 2011-03-09 2011-04-20 Antitope Ltd Antibodies
KR101517320B1 (ko) 2011-04-19 2015-05-28 메리맥 파마슈티컬즈, 인크. 단일특이적 및 이중특이적 항-igf-1r 및 항 erbb3 항체
SG194620A1 (en) 2011-04-25 2013-12-30 Daiichi Sankyo Co Ltd Anti-b7-h3 antibody
AU2012260601B2 (en) 2011-05-25 2018-02-01 Innate Pharma, S.A. Anti-KIR antibodies for the treatment of inflammatory disorders
US8753640B2 (en) 2011-05-31 2014-06-17 University Of Washington Through Its Center For Commercialization MIC-binding antibodies and methods of use thereof
US9403911B2 (en) 2011-06-06 2016-08-02 Board Of Regents Of The University Of Nebraska Compositions and methods for detection and treatment of cancer
ES2677367T3 (es) 2011-06-22 2018-08-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Anticuerpos anti-Axl y usos de los mismos
CA2854720C (en) 2011-11-11 2018-12-18 Rinat Neuroscience Corp. Antibodies specific for trop-2 and their uses
KR101535341B1 (ko) 2012-07-02 2015-07-13 한화케미칼 주식회사 Dll4에 특이적으로 결합하는 신규한 단일클론항체 및 이의 용도
SG11201408526SA (en) 2012-08-08 2015-03-30 Roche Glycart Ag Interleukin-10 fusion proteins and uses thereof
US20150218280A1 (en) 2012-08-10 2015-08-06 University Of Southern California CD20 scFv-ELPs METHODS AND THERAPEUTICS
WO2014033130A1 (en) 2012-08-28 2014-03-06 Institut Curie Cluster of differentiation 36 (cd36) as a therapeutic target for hiv infection
DK3199552T3 (da) 2012-11-20 2020-03-30 Sanofi Sa Anti-ceacam5-antistoffer og anvendelser heraf
EP2931750B8 (en) 2012-12-17 2021-11-03 Cell Medica Inc. Antibodies against il-1 beta
EP2958942B1 (en) 2013-02-20 2020-06-03 Novartis AG Effective targeting of primary human leukemia using anti-cd123 chimeric antigen receptor engineered t cells
WO2014159531A1 (en) 2013-03-14 2014-10-02 The Board Of Regents Of The University Of Texas System Monoclonal antibodies targeting epcam for detection of prostate cancer lymph node metastases
CA2913052A1 (en) 2013-05-24 2014-11-27 Board Of Regents, The University Of Texas System Chimeric antigen receptor-targeting monoclonal antibodies
KR102127408B1 (ko) 2014-01-29 2020-06-29 삼성전자주식회사 항 Her3 scFv 단편 및 이를 포함하는 항 c-Met/항 Her3 이중 특이 항체
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
FR3021970B1 (fr) 2014-06-06 2018-01-26 Universite Sciences Technologies Lille Anticorps dirige contre la galectine 9 et inhibiteur de l'activite suppressive des lymphocytes t regulateurs
CN113583131B (zh) 2014-08-19 2024-09-03 默沙东有限责任公司 抗tigit抗体
ES2862701T3 (es) 2014-12-22 2021-10-07 Univ Rockefeller Anticuerpos agonistas anti-MERTK y usos de los mismos
US10744157B2 (en) 2015-03-26 2020-08-18 The Trustees Of Dartmouth College Anti-MICA antigen binding fragments, fusion molecules, cells which express and methods of using
JP2018512892A (ja) 2015-04-17 2018-05-24 エルサリー バイオテックＥｌｓａｌｙｓｂｉｏｔｅｃｈ 抗ｔｙｒｏ３抗体及びその使用
TW201713699A (zh) 2015-08-06 2017-04-16 新加坡科技研究局 介白素２受體β（ＩＬ２Ｒβ）／共同γ鏈抗體
TWI811892B (zh) 2015-09-25 2023-08-11 美商建南德克公司 抗tigit抗體及使用方法
JP7037480B2 (ja) 2015-11-13 2022-03-16 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド がんの免疫療法のためのｎｋｇ２ｄ－ｉｇ融合タンパク質
SG11201807437XA (en) 2016-03-01 2018-09-27 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd Antibodies specific to human poliovirus receptor (pvr)
WO2017189526A1 (en) 2016-04-25 2017-11-02 Musc Foundation For Research Development Activated cd26-high immune cells and cd26-negative immune cells and uses thereof
AU2018205629A1 (en) * 2017-01-03 2019-07-11 Bioatla Llc Protein therapeutics for treatment of senescent cells
KR20200090742A (ko) * 2017-08-28 2020-07-29 알토 바이오사이언스 엘엘씨 Il-7 및 il-21에의 il-15 기반 융합
AU2019328313A1 (en) * 2018-08-30 2021-02-25 Immunitybio, Inc. Single-chain chimeric polypeptides and uses thereof
AU2019328290B2 (en) * 2018-08-30 2024-10-10 Immunitybio, Inc. Multi-chain chimeric polypeptides and uses thereof
US11730762B2 (en) * 2018-08-30 2023-08-22 HCW Biologics, Inc. Methods for stimulating proliferation or differentiation of an immune cell with a multi-chain chimeric polypeptide

Also Published As

Publication number Publication date
EP4157460A1 (en) 2023-04-05
JP2023527869A (ja) 2023-06-30
WO2021247604A1 (en) 2021-12-09
KR20230031280A (ko) 2023-03-07
CA3184756A1 (en) 2021-12-09
AU2021283199A1 (en) 2023-01-05

Similar Documents

Publication Publication Date Title
IL298608A (he) שיטות לטיפול בהפרעות הקשורות להזדקנות
MXPA05002791A (es) Oligonucleotidos antivirales complementarios sin secuencia.
BR0209658A (pt) Derivados de 4-amino-5-fenil-7-1ciclobutil-pirrolo [2,3-d] pirimidina
WO2021050953A8 (en) Compositions and methods for the delivery of therapeutic biologics for treatment of disease
WO2007062093A3 (en) Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor
CA2353553A1 (en) Method for the treatment of cerebral ischaemia and use of erythropoietin or erythropoietin derivatives for the treatment of cerebral ischaemia
WO2004096224A3 (en) Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells, or angiogenesis
BR0316157A (pt) Derivados de 4-amino-5-fenil-7-ciclohexil-pirrolo[2,3-d]pirimidina
PT1362600E (pt) Utilização tópica de iscos de nf-kb para o tratamento da dermatite atópica
WO2008033440A3 (en) Treatment of hyperproliferative diseases with anthraquinones
SA519410993B1 (ar) النشاط المضاد للبكتيريا لأوليجو سكاريد من جالاكتو وزيليتول في العلاجات الجلدية
WO2021041539A3 (en) Pyrido-indole analogues as gpx4 inhibitors
WO2002102311A3 (en) Nanoparticles for treating targeted tissues and cells
WO2019231725A3 (en) Treatment of gaucher disease
MX2021011289A (es) Composiciones que comprenden moduladores de isoenzima m2 muscular de piruvato cinasa pkm2 y metodos de tratamiento que usan las mismas.
CL2023000296A1 (es) Uso de dexpramipexol para el tratamiento del asma moderado a grave
WO2003103675A3 (en) COMBINATION THERAPIES FOR PURINOCEPTOR RELATED DISORDERS
WO2006096458A3 (en) Treatment of hyperproliferative diseases with anthraquinones
Rafiq et al. Comparison of topical 0.03% tacrolimus with 0.05% clobetasol in treatment of vitiligo
WO2002076393A3 (en) Antiagionecic, antitumor, chemopreventative agents
WO2004030623A3 (en) Nitroxide radioprotector formulations and methods of use
BR0308756A (pt) Combinação compreendendo um inibidor de cdk e doxorrubicina
MX2022002451A (es) Metodos para el tratamiento de la enfermedad cln2 en sujetos pediatricos.
WO2004100899A3 (en) Use of secretin in treatments of disorders associated with the amygdala
UA33545A (uk) Спосіб лікування дакріоциститу